SUVEN LIFE SCIENCES
|
SUVEN LIFE SCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -4.82 | -5.42 | -8.39 | -5.67 | -7.40 |
| CEPS(Rs) | -4.52 | -5.12 | -7.45 | -4.91 | -6.52 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 12.38 | 17.21 | 6.61 | 5.58 | 11.26 |
| Tax Rate(%) | 0.94 | - | - | 6.87 | 11.45 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -1,093.52 | -928.87 | -1,032.13 | -593.11 | -802.77 |
| EBIT Margin(%) | -904.65 | -870.48 | -1,024.33 | -567.83 | -734.32 |
| Pre Tax Margin(%) | -907.21 | -873.52 | -1,029.99 | -574.81 | -738.14 |
| PAT Margin (%) | -898.63 | -873.52 | -1,029.99 | -535.31 | -653.62 |
| Cash Profit Margin (%) | -843.03 | -825.19 | -992.90 | -503.07 | -624.70 |
| Performance Ratios | |||||
| ROA(%) | -27.37 | -34.54 | -57.51 | -28.99 | -27.07 |
| ROE(%) | -32.56 | -50.17 | -145.90 | -67.29 | -49.27 |
| ROCE(%) | -32.78 | -49.94 | -117.81 | -60.09 | -54.67 |
| Asset Turnover(x) | 0.03 | 0.04 | 0.06 | 0.05 | 0.04 |
| Sales/Fixed Asset(x) | 0.14 | 0.16 | 0.16 | 0.19 | 0.25 |
| Working Capital/Sales(x) | 0.05 | 0.06 | 0.20 | 0.16 | 0.37 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 7.10 | 6.33 | 6.35 | 5.34 | 4.04 |
| Receivable days | 32.67 | 28.38 | 47.15 | 54.60 | 62.22 |
| Inventory Days | 22.12 | - | 2.53 | 3.83 | - |
| Payable days | - | - | - | - | - |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -22.06 | -9.46 | -11.47 | -13.22 | -3.02 |
| Price/Book(x) | 8.05 | 2.82 | 14.02 | 12.61 | 1.90 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 171.92 | 64.46 | 113.42 | 63.12 | 17.99 |
| EV/Core EBITDA(x) | -18.83 | -7.44 | -11.13 | -11.79 | -2.55 |
| EV/EBIT(x) | -19.00 | -7.41 | -11.07 | -11.12 | -2.45 |
| EV/CE(x) | 7.44 | 2.33 | 6.65 | 3.83 | 0.94 |
| M Cap / Sales | 185.94 | 78.07 | 113.85 | 66.48 | 18.90 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -13.64 | 14.31 | -12.12 | -6.50 | -94.95 |
| Core EBITDA Growth(%) | 9.02 | 2.76 | -67.13 | 29.01 | -725.08 |
| EBIT Growth(%) | 10.25 | 2.86 | -58.53 | 27.70 | -5,215.23 |
| PAT Growth(%) | 11.15 | 3.06 | -69.08 | 23.42 | -294.15 |
| EPS Growth(%) | 11.15 | 35.37 | -48.03 | 23.42 | -294.16 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.01 | 0.02 | 0.01 |
| Current Ratio(x) | 18.99 | 3.29 | 1.57 | 1.79 | 1.33 |
| Quick Ratio(x) | 18.94 | 3.29 | 1.57 | 1.79 | 1.33 |
| Interest Cover(x) | -354.37 | -286.20 | -181.00 | -81.35 | -191.96 |
| Total Debt/Mcap(x) | - | - | - | - | 0.01 |
Compare Financial Ratios of peers of SUVEN LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUVEN LIFE SCIENCES | ₹2,634.6 Cr | -4.8% | -8.1% | 45.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,930.0 Cr | -1.4% | -7.1% | 48% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,524.0 Cr | 1.5% | -2.1% | 63% | Stock Analytics | |
| CIPLA | ₹118,828.0 Cr | -3.5% | -5.2% | 18% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,290.0 Cr | -3.9% | -10.1% | 10.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,280.3 Cr | -0.3% | -7.3% | 52.2% | Stock Analytics | |
SUVEN LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN LIFE SCIENCES | -4.8% |
-8.1% |
45.5% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
You may also like the below Video Courses
